The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
Silvia MartiniMaria Francesca DonatoChiara MazzarelliMaria RendinaUbaldo Visco-ComandiniDaniela FilìAlice GianstefaniStefano FagiuoliMario MelazziniSimona MontillaLuca PaniSandra PetragliaPierluigi RussoMaria Paola TrottaPaola CarraiPaolo Caraceninull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
These real-life data indicate that in waitlisted patients: (i) bridging antiviral therapy can be an option for patients still viraemic or negative <4 weeks at LT; and (ii) clinical improvement to a condition suitable for delisting can occur even in patients with advanced decompensated cirrhosis.
Keyphrases
- end stage renal disease
- ejection fraction
- prognostic factors
- heart failure
- peritoneal dialysis
- hepatitis c virus
- stem cells
- bone marrow
- machine learning
- human immunodeficiency virus
- patient reported outcomes
- hepatitis b virus
- deep learning
- artificial intelligence
- smoking cessation
- hiv infected
- cell therapy
- data analysis
- patient reported
- antiretroviral therapy